<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212742</url>
  </required_header>
  <id_info>
    <org_study_id>OLA-TMZ-RTE-01</org_study_id>
    <nct_id>NCT03212742</nct_id>
  </id_info>
  <brief_title>Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients</brief_title>
  <acronym>OLA-TMZ-RTE-01</acronym>
  <official_title>Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Stupp protocol is the standard treatment of glioblastoma multiform (GBM) which prognosis&#xD;
      remains poor.&#xD;
&#xD;
      The non-dividing nature of normal brain cells provides an opportunity to enhance the&#xD;
      therapeutic ratio by combining radiation with inhibitors of replication-specific DNA repair&#xD;
      pathways such poly(ADP-ribose) polymerase (PARP) inhibitors, thus inducing more cytotoxic&#xD;
      effects of DNA-damage related to treatment modalities, including alkylating reagents like&#xD;
      temozolomide (TMZ).&#xD;
&#xD;
      Olaparib, a potent PARP inhibitor, overcomes apoptotic resistance and sensitizes GBM cells&#xD;
      for death receptor-mediated apoptosis induced by TRAIL (Tumor necrosis factor-Related&#xD;
      Apoptosis Inducing Ligand). Moreover, inhibition of PARP activity increases cellular&#xD;
      sensitivity to ionizing radiation: it was even suggested to be more pronounced in tumors than&#xD;
      in normal tissue.&#xD;
&#xD;
      Lastly, progress in technical imaging and intensity-modulated-radiotherapy (IMRT) techniques&#xD;
      provide new possibilities for sparing healthy tissues.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HGGs are the most common and most aggressive primary brain tumor. There is a real need to&#xD;
      improve care management of GBM patients. Attempts to achieve cure by increasing radiation&#xD;
      dose result in unacceptable neurotoxicity. As for radiosensitizers, they can exacerbate&#xD;
      normal tissue damage.&#xD;
&#xD;
      Since GBM represent a rapidly dividing cell population within the nonreplicating normal&#xD;
      brain, the therapeutic ratio may be enhanced by specific radiosensitization of proliferating&#xD;
      cells. Resistance to apoptosis is a paramount issue in the treatment of HGG. Targeting PARP&#xD;
      by the inhibitors like olaparib can reduce proliferation and lowers the apoptotic threshold&#xD;
      of HGG (effect showed in vivo and in vitro).&#xD;
&#xD;
      In this context, we propose a phase I-IIa trail to investigate the toxicity and efficacy of&#xD;
      olaparib and TMZ concomitantly with radiotherapy in first line treatment of unresectable high&#xD;
      risk HGG.&#xD;
&#xD;
      Correlation between treatment response and tumor profiling will allow us to identify&#xD;
      biomarkers that can be useful in treatment improvement and/or present a prognostic value.&#xD;
      Then, the transfer of this approach will be evaluated in terms of compatibility with the&#xD;
      requirements of diagnostic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Recommended Phase II Dose (RP2D) - Phase I</measure>
    <time_frame>The RP2D will be evaluated 4 weeks after the end of radiotherapy</time_frame>
    <description>The primary objective for the phase I is to determine the Recommended Phase II Dose (RP2D) of olaparib combined with the Stupp protocol (TMZ and concomitant fractionated radiotherapy: 60Gy/30 fractions/6 weeks) in first line treatment of patients with unresectable high-grade gliomas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival - Phase II</measure>
    <time_frame>18 months after the first administration of treatment</time_frame>
    <description>The primary objective for the phase II is to assess the 18-month overall survival of the combination</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Malignant Gliomas</condition>
  <condition>Radiotherapy</condition>
  <condition>PARP Inhibitor</condition>
  <arm_group>
    <arm_group_label>IMRT - Temozolomide - Olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The therapeutic regimen will be divided into 2 different periods:&#xD;
Radiotherapy period The patient will start IMRT (60Gy/30fr/6 weeks), TMZ(Temozolomide) chemotherapy (75mg/m²/day), and olaparib on the same day, on a Monday (day 1), within 6 weeks after surgery. The daily dose of TMZ (75 mg/m²) will be continued until the end of radiotherapy (6 weeks) and olaparib will be continued with the same dose until 4 weeks after the end of IMRT, as a single agent.&#xD;
Maintenance period TMZ will then be re-introduced 4 weeks after the end of IMRT at the dose of 150 mg/m2/day on days 1 to 5 every 28 days, for a total of 6 cycles. Concomitantly, olaparib will be daily given at the maintenance dose level up to confirmed disease progression or unacceptable toxicities.&#xD;
We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously</description>
    <arm_group_label>IMRT - Temozolomide - Olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide (TMZ)</intervention_name>
    <description>TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.</description>
    <arm_group_label>IMRT - Temozolomide - Olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT (Intensity Modulated Radiation Therapy)</intervention_name>
    <description>Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)</description>
    <arm_group_label>IMRT - Temozolomide - Olaparib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed informed consent prior to any study specific procedures&#xD;
&#xD;
          -  Histologically-confirmed diagnosis of glioblastoma (IDH-wildtype, IDH-mutant or NOS,&#xD;
             except gliosarcoma), non resectable or partially resectable with a residual tumor on&#xD;
             pre-radiotherapy MRI. The presence of a residual disease will be assessed by the&#xD;
             radiologist on the pre-radiotherapy imaging as compared with initial imaging.&#xD;
&#xD;
          -  IMRT must start within 6 weeks after histological diagnosis&#xD;
&#xD;
          -  Age between 18 and 70 years ;&#xD;
&#xD;
          -  Neurologically asymptomatic or pauci-symptomatic patients. Patients with moderated&#xD;
             neurological symptoms without systemic corticosteroids treatment or with a stable dose&#xD;
             of corticosteroids during the study as long as these were started at least 4 weeks&#xD;
             prior to treatment can be included.&#xD;
&#xD;
          -  Adequate bone marrow and organ function measured within 15 days prior to&#xD;
             administration of study treatment as defined below:&#xD;
&#xD;
               -  Haemoglobin ≥ 10.0 g/dL with no blood transfusions (packed red blood cells and&#xD;
                  platelet transfusions) in the past 28 days before start of treatment&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
                  o No features suggestive of MDS/AML on peripheral blood smear&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
               -  White blood cells (WBC) &gt; 3x109/L&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal&#xD;
&#xD;
               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal&#xD;
&#xD;
               -  Creatinine clearance estimated using the Cockcroft-Gault equation of ≥51 mL/min:&#xD;
&#xD;
        Estimated creatinine clearance = [(140-age(years)) x weight(kg) (x Fsex) ] / [serum&#xD;
        creatinine (mg/dL) x 72] where Fsex=0.85 for females and Fsex=1 for males.&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Patients must have a life expectancy ≥ 16 weeks.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) and men under efficient contraception during&#xD;
             treatment and at least 6 months after the end of treatment.&#xD;
&#xD;
          -  Evidence of non-childbearing status for women of childbearing potential: negative&#xD;
             urine or serum pregnancy test within 28 days of study treatment, confirmed prior to&#xD;
             treatment on day 1.&#xD;
&#xD;
          -  Postmenopausal (if applicable) is defined as:&#xD;
&#xD;
               -  Amenorrheic for 1 year or more following cessation of exogenous hormonal&#xD;
                  treatments,&#xD;
&#xD;
               -  LH and FSH levels in the post-menopausal range for women under 50,&#xD;
&#xD;
               -  radiation-induced oophorectomy with last menses &gt;1 year ago,&#xD;
&#xD;
               -  chemotherapy-induced menopause with &gt;1 year interval since last menses,&#xD;
&#xD;
               -  or surgical sterilisation (bilateral oophorectomy or hysterectomy).&#xD;
&#xD;
          -  Male patients and their partners, who are sexually active and of childbearing&#xD;
             potential, must agree to the use of two highly effective forms of contraception in,&#xD;
             throughout the period of taking study treatment and for 3 months after last dose of&#xD;
             study drug(s) to prevent pregnancy in a partner.&#xD;
&#xD;
          -  Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
          -  Subjects affiliated to an appropriate social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior radiotherapy to brain&#xD;
&#xD;
          -  Any prior chemotherapy or immunotherapy&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca&#xD;
             staff and/or staff at the study site)&#xD;
&#xD;
          -  Candidate for a concomitant therapy with Tumor-Treating Fields during the maintenance&#xD;
             treatment [70]&#xD;
&#xD;
          -  Previous enrolment in the present study&#xD;
&#xD;
          -  Participation in another clinical trial protocol within 30 days prior to enrolment;&#xD;
&#xD;
          -  Any previous treatment with a PARP inhibitor, including olaparib.&#xD;
&#xD;
          -  Patients with second primary cancer, except: adequately treated non-melanoma skin&#xD;
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumours&#xD;
             curatively treated with no evidence of disease for ≥ 5 years&#xD;
&#xD;
          -  Gadolinium hypersensitivity, or any contraindication to undergo MRI examination&#xD;
             (Pacemaker, brain aneurysms clips)&#xD;
&#xD;
          -  Patients who had no initial pre-surgery contrast enhanced MRI scan including the&#xD;
             standard sequences (T1 non enhanced, T1 contrast enhanced, T2 FLAIR)&#xD;
&#xD;
          -  Patients receiving any systemic chemotherapy, radiotherapy (except for palliative&#xD;
             reasons), within 2 weeks from the last dose prior to study treatment. The patient can&#xD;
             receive a stable dose of bisphosphonates for bone metastases, before and during the&#xD;
             study as long as these were started at least 4 weeks prior to treatment with study&#xD;
             drug.&#xD;
&#xD;
          -  Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin,&#xD;
             clarithromycin, protease inhibitors boosted) or moderate CYP3A inhibitors (eg.&#xD;
             ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout&#xD;
             period prior to starting olaparib is 2 weeks.&#xD;
&#xD;
          -  Concomitant use of known strong (eg. phenobarbital, phenytoin, rifampicin, rifabutin,&#xD;
             rifapentine, carbamazepine, and St John's Wort ) or moderate CYP3A inducers (eg.&#xD;
             bosentan, modafinil). The required washout period prior to starting olaparib is 5&#xD;
             weeks for phenobarbital and 3 weeks for other agents.&#xD;
&#xD;
          -  Resting ECG with QTc &gt; 470 msec detected on 2 or more time points within a 24 hour&#xD;
             period or family history of long QT syndrome. If ECG demonstrates QTc &gt; 470 msec,&#xD;
             patient will be eligible only if repeat ECG demonstrates QTc ≤470 msec;&#xD;
&#xD;
          -  Blood transfusions within 1 month prior to study start&#xD;
&#xD;
          -  Previous allogenic bone marrow transplant or double umbilical cord blood&#xD;
             transplantation (dUCBT)&#xD;
&#xD;
          -  Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features&#xD;
             suggestive of MDS/AML.&#xD;
&#xD;
          -  Major surgery within 14 days of starting study treatment and patients must have&#xD;
             recovered from any effects of any major surgery.&#xD;
&#xD;
          -  Patients considered a poor medical risk due to a serious, uncontrolled medical&#xD;
             disorder, non-malignant systemic disease or active, uncontrolled infection. Examples&#xD;
             include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3&#xD;
             months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal&#xD;
             cord compression (untreated and unstable for at least 28 days prior to study entry),&#xD;
             superior vena cava syndrome, extensive bilateral lung disease on HRCT scan or any&#xD;
             psychiatric disorder that prohibits obtaining informed consent.&#xD;
&#xD;
          -  Patients unable to swallow orally administered medication and patients with&#xD;
             gastrointestinal disorders likely to interfere with absorption of the study medication&#xD;
             (inflammatory bowel disease, major bowel resection …)&#xD;
&#xD;
          -  Pregnant or breast feeding women.&#xD;
&#xD;
          -  Immunocompromised patients, e.g., patients who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV) and are receiving antiviral therapy.&#xD;
&#xD;
          -  Patients with known active hepatitis (i.e., Hepatitis B or C) due to risk of&#xD;
             transmitting the infection through blood or other body fluids.&#xD;
&#xD;
          -  Patients with a known hypersensitivity to olaparib or any of the excipients of the&#xD;
             product.&#xD;
&#xD;
          -  For temozolomide treatment, patients with a known galactose intolerance, a Lapp&#xD;
             lactase deficit or a glucose or galactose malabsorption syndrome (rare hereditary&#xD;
             diseases)&#xD;
&#xD;
          -  Patients with uncontrolled epileptic seizures.&#xD;
&#xD;
          -  Neurological, addictive or psychiatric disorder;&#xD;
&#xD;
          -  Lack of availability for clinical follow-up assessments;&#xD;
&#xD;
          -  Persons protected by a legal regime (guardianship, trusteeship).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dinu STEFAN, MD</last_name>
    <phone>33 2 31 45 50 50</phone>
    <email>d.stefan@baclesse.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Michel GRELLARD</last_name>
    <email>jm.grellard@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte BRONNIMANN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aymeri HUCHET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte BRONNIMANN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amandine QUIVY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marine GROS-GOUPIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>AMAURY DASTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dinu STEFAN, MD</last_name>
      <phone>33 2 31 45 50 50</phone>
      <email>d.stefan@baclesse.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Michel GRELLARD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dinu STEFAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien GEFFRELOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ioana HRAB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Emmanuel BRACHET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William KAO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélanie DOS SANTOS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul LESUEUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emeline MERIAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Pierre SUNYACH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Pierre SUNYACH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronan TANGUY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coralie MONCHARMONT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier FRAPPAZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux universitaires La Pitié Salpétrière - Charles Foix</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loic FEUVRET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Loic FEUVRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence LAIGLE-DONADEY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khe HOANG-XUAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed IBDAIH, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hamid MAMMAR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hamid MAMMAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence BOZEC LE MOAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coraline DUBOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia TRESCA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia MOISSON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth MOYAL COHEN-JONATHAN, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth MOYAL COHEN-JONATHAN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ioana CARPUC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre DELORD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile GANDY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Alberto GOMEZ-ROCA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anouchka MODESTO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaud VALENTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

